{
    "clinical_study": {
        "@rank": "135986", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This observational study will evaluate the use and efficacy of Mircera (methoxy polyethylene\n      glycol-epoetin beta) in anemia patients with chronic kidney disease (CKD) stage III-IV not\n      on dialysis or CKD stage V on dialysis. Patients will be followed during 12 months of\n      treatment."
        }, 
        "brief_title": "An Observational Study of Mircera in Patients With Chronic Renal Anemia on Dialysis (CKD Stage V) or Not on Dialysis (CKD Stage III-IV)", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Anemia", 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Renal Insufficiency, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Patients with chronic renal anemia with stage III-IV CKD not on dialysis and who are,\n             in the opinion of the treating physician, not expected at baseline to require\n             dialysis within 12 months\n\n          -  Patients with chronic renal anemia with stage V CKD on dialysis\n\n          -  No contraindication to ESA treatment\n\n        Exclusion Criteria:\n\n          -  Uncontrolled hypertension\n\n          -  Hypersensitivity to the active substance or any other of the excipients of Mircera\n             and other ESAs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Anemia patients with chronic kidney disease (CKD) stage III-IV not on dialysis or CKD\n        stage V on dialysis"
            }
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01667380", 
            "org_study_id": "ML25617"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Podgorica", 
                    "country": "Montenegro", 
                    "zip": "81 000"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Montenegro"
        }, 
        "number_of_groups": "1", 
        "official_title": "Non-interventional Study on the Use of Mircera in the Treatment of Chronic Renal Anemia in Patients With Chronic Kidney Disease Stages III-IV Not on Dialysis and in Patients on Stage V on Hemodialysis", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML25617 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Montenegro: Agency for Medicines and Medical Devices of Montenegro"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Dosage/schedule of Mircera treatment in clinical practice", 
            "safety_issue": "No", 
            "time_frame": "approximately 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01667380"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of patients with mean Hb level 10-12 g/dL 10 to 12 months after initiation of treatment", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }, 
            {
                "measure": "Change in Hb levels", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Month 12"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}